한빛사
>
한빛사논문
한빛사논문
- 조회521
Cancer Immunol. Res., Sep 12 2023 | https://doi.org/10.1158/2326-6066.CIR-23-0667
Let the Guard Down: cAMP Activators Can Improve Immunotherapy in GBM.
Juyeun Lee 1, Kristen E Kay 1,2, Michael A Vogelbaum 3, Justin D Lathia 1,4,5
1Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
2Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio.
3Department of NeuroOncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
4Case Comprehensive Cancer Center, Cleveland, Ohio.
5Rose Ella Burkhardt Brain Tumor Center, Cleveland Clinic, Cleveland, Ohio.
Corresponding Author: Justin D. Lathia
Abstract
Enhancing T-cell infiltration into glioblastoma (GBM) tumors has proven challenging yet remains crucial for improving the efficacy of immunotherapy for patients with this deadly cancer. In this issue, Qin, Huang, Li, and colleagues find that inhibiting vasculature formation driven by cancer stem cells is a promising target to enhance immunotherapy in GBM. See related article by Qin et al. (2).
논문정보
- Editorial
- 2023년 09월 (BRIC 등록일 2023-09-15)
- 국외 연구진
- 생명과학 > 면역학
댓글 작성 로그인
팝업 닫기관련 링크
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
